{
    "root": "1c6dff5c-3eab-49c1-8387-04a37a3fbbf5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PERJETA",
    "value": "20250507",
    "ingredients": [
        {
            "name": "PERTUZUMAB",
            "code": "K16AIQ8CTM",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06366"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "perjeta her2/neu receptor antagonist indicated : combination trastuzumab docetaxel treatment adults her2-positive metastatic breast cancer ( mbc ) received prior anti-her2 therapy chemotherapy metastatic disease . ( 1.1 ) combination trastuzumab chemotherapy neoadjuvant treatment adults her2-positive , locally advanced , inflammatory , early stage breast cancer ( either greater 2 cm diameter node positive ) part complete treatment regimen early breast cancer . ( 1.2 , 2.2 , 14.2 ) adjuvant treatment adults her2-positive early breast cancer high risk recurrence ( 1.2 , 2.2 , 14.3 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous infusion . administer intravenous push bolus . ( 2.5 ) her2 testing : perform using fda-approved tests laboratories demonstrated proficiency . ( 2.1 ) initial perjeta dose 840 mg administered 60-minute intravenous infusion , followed every 3 weeks thereafter 420 mg administered 30 60 minute intravenous infusion . ( 2.3 ) mbc : administer perjeta , trastuzumab trastuzumab hyaluronidase-oysk , docetaxel every 3 weeks . ( 2.3 ) neoadjuvant : administer perjeta , trastuzumab trastuzumab hyaluronidase-oysk , chemotherapy preoperatively every 3 weeks 3 6 cycles . ( 2.3 ) adjuvant : administer perjeta , trastuzumab trastuzumab hyaluronidase-oysk , chemotherapy postoperatively every 3 weeks total 1 year ( 18 cycles ) . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "perjeta contraindicated patients known hypersensitivity pertuzumab excipients [ ( 5.4 ) ] .",
    "indications_original": "PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 )",
    "contraindications_original": "For intravenous infusion only. Do not administer as an intravenous push or bolus. ( 2.5 ) HER2 testing:  Perform using FDA-approved tests by laboratories with demonstrated proficiency. ( 2.1 ) The initial PERJETA dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion. ( 2.3 ) MBC: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and docetaxel every 3 weeks. ( 2.3 ) Neoadjuvant:  Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy preoperatively every 3 weeks for 3 to 6 cycles. ( 2.3 ) Adjuvant: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy postoperatively every 3 weeks for a total of 1 year (up to 18 cycles). ( 2.3 )",
    "adverseReactions_original": "PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "PERJETA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06366"
        }
    ]
}